Literature DB >> 20425429

Application of immunotherapy in pediatric leukemia.

Alan S Wayne1.   

Abstract

Despite great progress in the curative treatment of leukemia in pediatrics, current therapies are associated with multiple toxicities and the prognosis after relapse is guarded. Novel approaches are needed to overcome resistance to standard therapy and decrease adverse effects. The efficacy of allogeneic stem cell transplantation and the demonstration of a graft-versus-leukemia effect suggest that immune-based therapies can be effective in the treatment of childhood leukemia. Efforts to apply new immunotherapy approaches to the treatment of leukemia in pediatrics have recently begun. The optimal reagents, methods, and regimens have yet to be fully defined. Ongoing clinical trials offer promise in that regard.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20425429     DOI： 10.1007/s11899-009-0022-5

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  43 in total

Review 1.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review.

Authors:  Denise M Oliansky; J Douglas Rizzo; Peter D Aplan; Robert J Arceci; Louis Leone; Yaddanapudi Ravindranath; Jean E Sanders; Franklin O Smith; Fiona Wilmot; Philip L McCarthy; Theresa Hahn
Journal:  Biol Blood Marrow Transplant       Date:  2007-01       Impact factor: 5.742

2.  Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma.

Authors:  P Dinndorf; M Krailo; W Liu-Mares; S Frierdich; P Sondel; G Reaman
Journal:  J Immunother       Date:  2001 Nov-Dec       Impact factor: 4.456

3.  Progress in the curative treatment of childhood hematologic malignancies.

Authors:  Alan S Wayne; Gregory H Reaman; Lee J Helman
Journal:  J Natl Cancer Inst       Date:  2008-09-09       Impact factor: 13.506

4.  Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial.

Authors:  F Locatelli; M Zecca; R Rondelli; F Bonetti; G Dini; A Prete; C Messina; C Uderzo; M Ripaldi; F Porta; G Giorgiani; E Giraldi; A Pession
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

5.  Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.

Authors:  Selim Corbacioglu; Stefan Eber; Tayfun Gungor; Jorg Hummerjohann; Felix Niggli
Journal:  J Pediatr Hematol Oncol       Date:  2003-04       Impact factor: 1.289

6.  Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.

Authors:  Edwin Bremer; Douwe F Samplonius; Matthias Peipp; Linda van Genne; Bart-Jan Kroesen; Georg H Fey; Martin Gramatzki; Lou F M H de Leij; Wijnand Helfrich
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

7.  Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia.

Authors:  A Yoshimi; P Bader; S Matthes-Martin; J Starý; P Sedlacek; U Duffner; T Klingebiel; D Dilloo; W Holter; F Zintl; B Kremens; K-W Sykora; C Urban; H Hasle; E Korthof; T Révész; A Fischer; P Nöllke; F Locatelli; C M Niemeyer
Journal:  Leukemia       Date:  2005-06       Impact factor: 11.528

8.  Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes.

Authors:  J H Falkenburg; A R Wafelman; P Joosten; W M Smit; C A van Bergen; R Bongaerts; E Lurvink; M van der Hoorn; P Kluck; J E Landegent; H C Kluin-Nelemans; W E Fibbe; R Willemze
Journal:  Blood       Date:  1999-08-15       Impact factor: 22.113

9.  Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy.

Authors:  E C Wong; V E Maher; K Hines; J Lee; C S Carter; T Goletz; W Kopp; C L Mackall; J Berzofsky; E J Read
Journal:  Cytotherapy       Date:  2001       Impact factor: 5.414

10.  Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin.

Authors:  C M Zwaan; D Reinhardt; H Jürgens; D R Huismans; K Hählen; O P Smith; A Biondi; E R van Wering; J Feingold; G J L Kaspers
Journal:  Leukemia       Date:  2003-02       Impact factor: 11.528
View more
  1 in total

Review 1.  Immunotherapy of childhood cancer: from biologic understanding to clinical application.

Authors:  Alan S Wayne; Christian M Capitini; Crystal L Mackall
Journal:  Curr Opin Pediatr       Date:  2010-02       Impact factor: 2.856
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.